# Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
Canonical URL: https://biopharmsignal.com/news/XAIR/beyond-air-schedules-fiscal-year-end-2026-financial-results-conference-call-and--03178c17
Ticker: XAIR
Company: Beyond Air
Source: Beyond Air
Published: 2026-06-22 20:01 EST
## Summary

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device...

## Article Body
Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day.

| Conference Call & Webcast |  |
| --- | --- |
| Friday, June 26th @ 8:00 a.m. ET |  |
| Domestic: | 1-877-407-0784 |
| International: | 1-201-689-8560 |
| Conference ID: | 13761239 |

Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website ( click here ) or directly ( click here ). An online replay will be available on the Company’s website or via the direct link an hour after the call.

About Beyond Air, Inc. Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net .

CONTACTS:

Corey Davis, Ph.D. LifeSci Advisors, LLC Cdavis@lifesciadvisors.com (212) 915-2577
## Recent Company News
- 2026-06-26 11:00 EST — [Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/XAIR/beyond-air-reports-fourth-quarter-and-full-year-2026-financial-results-and-provi-8c4a9c6f) — Source: Beyond Air
- 2026-06-22 20:01 EST — [Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast](https://biopharmsignal.com/news/XAIR/beyond-air-schedules-fiscal-year-end-2026-financial-results-conference-call-and--03178c17) — Source: Beyond Air
- 2026-06-10 12:00 EST — [Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting](https://biopharmsignal.com/news/XAIR/beyond-air-inc-urges-stockholders-to-vote-for-all-proposals-ahead-of-the-upcomin-31020f6e) — Source: Beyond Air
- 2026-06-01 12:00 EST — [Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing](https://biopharmsignal.com/news/XAIR/beyond-air-receives-nasdaq-hearing-panel-decision-granting-continued-listing-fe2e861e) — Source: Beyond Air
- 2026-04-20 12:00 EST — [Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026](https://biopharmsignal.com/news/XAIR/beyond-cancer-reports-updated-survival-and-safety-data-from-phase-1-uno-trial-pr-2ccd5ce5) — Source: Beyond Air
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)